ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,440Medicare Part D Prescriptions Filled, Including Refills

Rank: 49 out of 393

$496K Total Retail Price of All Prescriptions

Rank: 63 out of 393

770 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
11% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 770 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

13% of this provider’s 770 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 9,661 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

14% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
SIMVASTATIN 723 691 1 1
LISINOPRIL 682 667 2 2
LEVOTHYROXINE SODIUM 466 446 3 3
AMLODIPINE BESYLATE 434 429 4 4
OMEPRAZOLE 363 311 5 6
HYDROCODONE-ACETAMINOPHEN 329 318 S3 6 5
METOPROLOL TARTRATE 320 313 7 9
LOSARTAN POTASSIUM 294 276 8 12
LOVASTATIN 261 253 9 14
ALENDRONATE SODIUM 247 236 10 16
ATENOLOL 244 241 11 13
HYDROCHLOROTHIAZIDE 202 189 12 10
METFORMIN HCL 195 183 13 7
AZITHROMYCIN 193 177 14 35
METOPROLOL SUCCINATE 179 166 15 22
ATORVASTATIN CALCIUM 176 155 16 19
FUROSEMIDE 164 164 17 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 159 153 18 24
ZOLPIDEM TARTRATE 135 131 19 11
WARFARIN SODIUM 130 123 20 17
PRAVASTATIN SODIUM 118 113 21 18
MELOXICAM 104 103 22 58
FLUTICASONE PROPIONATE 102 99 23 27
POTASSIUM CHLORIDE 101 99 24 20
GLIPIZIDE 100 100 25 32
GABAPENTIN 91 81 26 15
FLUOXETINE HCL 89 78 27 37
ADVAIR DISKUS 89 87 27 53
CITALOPRAM HBR 87 71 29 23
TRIAMTERENE-HCTZ 79 65 30 49
DOXAZOSIN MESYLATE 74 74 31 83
LOSARTAN-HYDROCHLOROTHIAZIDE 69 69 32 31
BENAZEPRIL HCL 68 64 33 40
ALLOPURINOL 67 67 34 26
SPIRIVA 64 56 35 41
TAMSULOSIN HCL 64 62 35 25
TERAZOSIN HCL 63 63 37 38
DILTIAZEM 24HR CD 61 59 38 152
TRAMADOL HCL 59 53 39 30
PREDNISONE 58 49 40 65
TIZANIDINE HCL 58 54 40 97
PAROXETINE HCL 55 46 42 61
GLIPIZIDE ER 53 53 43 76
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 25, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.